Results 231 to 240 of about 2,555,654 (307)

How Hot Is Too Hot? Fever Thresholds for Initiating Antibiotics in Children With Haematological Malignancies

Acta Paediatrica, EarlyView.
C. S. V. Henriksen, U. Nygaard, G. Petersen, J. Brok, L. L. Hjalgrim, N. V. Vissing, M. B. Mønster   +6 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Role of essential and trace elements in chronic myeloid leukemia: associations with serum trace element profiles and hematological parameters. [PDF]

Front Aging
Yadav AK, Choudhary U, Aich A, Meena LP, Singh R, Tiwari S, Ashish A.   +6 more
europepmc   +1 more source

Leveraging venetoclax‐induced autophagy to enhance AUTAC‐mediated Mcl1 degradation and overcome resistance in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Ahmed M. Elshazly, Nayyerehalsadat Hosseini, Janakiram R. Vangala, Xiaoyan Hu, Steven Grant, Senthil K. Radhakrishnan   +5 more
wiley   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Roth Spots As the Initial Manifestation of Accelerated-Phase Chronic Myeloid Leukemia. [PDF]

Cureus
Benchekroun M, Hamidi S, Fakhir B, Benchekroun Belabbas S, Cherkaoui LO.   +4 more
europepmc   +1 more source

From infusion to pills in acute myeloid leukaemia: Reorganizing care beyond the infusion unit

British Journal of Haematology, EarlyView.
Fortunato Morabito, Enrica Antonia Martino, Antonella Bruzzese, Nicola Amodio, Santino Caserta, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

British Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra, Francesco Niro, Marco Mergiotti, Giovanni Gavatorta, Emilio Hirsch, Alessandra Ghigo   +5 more
wiley   +1 more source

Delayed Gastric Bleeding in a Patient With Chronic Myeloid Leukemia: A Case of Post-Biopsy Bleeding. [PDF]

DEN Open
Kosaka Y, Yamane H, Nakanishi H, Takigawa N.   +3 more
europepmc   +1 more source

Inhibition of the MER tyrosine kinase ameliorates pulmonary fibrosis by suppressing macrophage M2 polarisation and osteopontin signalling

British Journal of Pharmacology, EarlyView.
Background and Purpose The MER proto‐oncogene tyrosine kinase (MERTK) has been implicated in the pathogenesis of pulmonary fibrosis (PF), and MERTK inhibition has been shown to ameliorate PF. However, the mechanisms remain unclear. Here, we have investigated how MERTK inhibition attenuates bleomycin (BLM)‐induced PF in mice and to elucidate the ...
Juan Li, Xiangsheng Yang, Xiao Xiao Tang
wiley   +1 more source